← Issue №10/ week of Sep 6, 2026/ the whole section, in full

Endoscopy, in full.

All 15 Endoscopy papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 15, in full

most clinically useful first · the 1 the issue led with is ruled in green
Endoscopy guideline · Sep 3, 2026 · Endoscopy · IF 11.8

Biliary stricture management: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Guideline / reviewbiliary strictureERCPguideline
Clinical takeawayFollow ESGE guidelines for stent selection and management in biliary strictures: use MPS for postcholecystectomy strictures, FCSEMS for chronic pancreatitis strictures (6-12 months) when >2 cm from hepatic confluence, and balloon dilation alone for PSC strictures (avoid stenting). Avoid USEMS for unconfirmed etiology. For hilar malignant obstruction, use ERCP for Bismuth types I-II and ERCP/EUS-BD for Bismuth III-IV over PTBD.
What it foundESGE provides specific stent and dilation recommendations for benign and malignant biliary strictures, including MPS for postcholecystectomy strictures, FCSEMS for chronic pancreatitis strictures (6-12 months) when located >2 cm distally from the main hepatic confluence, and balloon dilation alone for PSC strictures (no added benefit of stenting, which may increase adverse events). Avoid USEMS for unconfirmed etiology and prefer ERCP over PTBD for hilar malignant obstruction (Bismuth types I-II). For Bismuth III-IV, ERCP or combined ERCP/EUS-BD is preferable over primary PTBD.
ContextRefines and standardizes current practice with evidence-based recommendations for stent use and drainage strategies across various biliary stricture etiologies, including location-specific and population-specific guidance.
Measured against the standard of care· ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis)

Decision at stakethe management of benign biliary strictures with multiple plastic stents or FCSEMS

… Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. … High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnosis is unchanged and still follows the separate ESGE diagnostic guideline (Endoscopy 2025;57:166-185). Start with MRI/MRCP plus laboratory tests, read CA19-9 only after decompression, and check IgG4 when IgG4-related sclerosing cholangitis is suspected. For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. For perihilar strictures, sample by ERCP first and move to cholangioscopy-guided biopsy if the result is indeterminate. Do not place an uncovered SEMS (USEMS) until malignancy is confirmed. Management now follows the 2026 ESGE biliary stricture management guideline, which replaces the 2018 stenting guideline and brings it into line with the 2022 therapeutic EUS guideline. Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. Anastomotic strictures after liver transplant get MPSs, or a temporary FCSEMS if more than 2 cm below the confluence. Nonanastomotic post-transplant strictures that can be treated endoscopically get MPSs plus balloon dilation if needed. Chronic pancreatitis strictures get a temporary 8-10 mm FCSEMS for 6-12 months. High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. Endotherapy is indicated for a benign stricture with liver tests raised for more than 1 month and/or cholangitis. Malignant distal: drain before surgery only selectively (cholangitis, severe jaundice or pruritus, delayed surgery). When drainage is needed before surgery or neoadjuvant therapy, or for palliation, place a 10-mm SEMS endoscopically. Endoscopic drainage is preferred over surgery or PTBD for inoperable obstruction. Malignant hilar: manage in high-volume centres with a hepatobiliary multidisciplinary team (MDT). ERCP is preferred over PTBD for preoperative drainage. Palliate Bismuth I-II with ERCP. For Bismuth III-IV, ERCP or ERCP combined with EUS-guided drainage (EUS-BD) is preferred over primary PTBD, with PTBD as a complement if needed. For proven Bismuth II-IV, aim to drain more than 50%, ideally 70% or more, of the viable nonatrophic liver volume using several routes as needed. Use plastic stents when the drainage strategy is undefined or the centre is not expert. USEMS are for expert centres when the diagnosis is proven, the tumour is unresectable, and complete drainage is predicted. After failed or unfeasible ERCP, EUS-BD is recommended over PTBD. Use hepaticogastrostomy (EUS-HGS) if there is a duodenal stricture, and EUS-HGS or choledochoduodenostomy (EUS-CDS) if there is not. PTBD is used if EUS-BD fails. In surgically altered anatomy, benign disease gets enteroscopy-assisted ERCP first; malignant disease gets enteroscopy-assisted ERCP or EUS-BD. Give antibiotics before ERCP in selected cases: predicted incomplete drainage, hilar strictures, immunocompromised patients, PSC, cholangioscopy. This follows the ESGE ERCP-adverse-events guideline. Etiology-specific care (Strasberg injuries, IgG4-SC, Mirizzi, choledochal cysts) is unchanged.

ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis) · reviewed 2026-10-11 ↗
Lemmers A … Triantafyllou K · Endoscopy · IF 11.8 · PubMed ↗Permalink
Endoscopy rct · n=813 · Sep 1, 2026 · UEG Journal · IF 5.6

Acetate- Versus Lactate-Buffered Crystalloids for Prevention of Post-ERCP Pancreatitis in Patients Without Access to Rectal NSAIDs: A Multicentre Double-Blind Randomized Trial.

New evidenceERCPacute pancreatitisendoscopy quality
Clinical takeawayContinue using lactated Ringer's solution as the first-line crystalloid for aggressive hydration in patients at moderate-to-high PEP risk when rectal NSAIDs are unavailable.
What it foundPEP occurred in 12.4% of the LR group and 11.5% of the AC group (RR 0.93; 95% CI, 0.64-1.35; P=0.70), with no severe PEP or fluid overload.
ContextConfirms current practice: lactated Ringer's remains the preferred crystalloid for PEP prevention in settings without rectal NSAIDs.
Reinforcessuggested applicable standard· American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437

Decision at stakeusing lactated Ringer's solution for aggressive hydration to prevent post-ERCP pancreatitis

… Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose acute pancreatitis (AP) by the Atlanta criteria (2 of 3: characteristic epigastric/LUQ pain, lipase or amylase >3x ULN [lipase preferred for specificity/duration], or characteristic imaging). ACG 2024 stratifies severity risk using SIRS on admission plus bedside risk factors, rising/elevated BUN, rising/elevated hematocrit (>44), obesity (BMI>30), extrapancreatic fluid collections/pleural effusion/infiltrates, altered mental status, and older age/comorbidities, rather than mandating a formal BISAP or APACHE II composite score. Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). Start oral low-fat solid food within 24-48h as tolerated in mild disease; if enteral feeding is needed for moderately severe/severe disease, prefer nasogastric over nasojejunal with small-peptide/medium-chain-triglyceride formula and continuous (not bolus/cyclic) feeding; avoid parenteral nutrition if possible. Do not give prophylactic antibiotics, even in severe disease or sterile necrosis; reserve antibiotics for suspected infected necrosis (typically arising 10-14 days in), and choose agents that penetrate pancreatic necrosis while together covering both gut-derived gram-negative enterics and anaerobes, a carbapenem supplies this as monotherapy, whereas a fluoroquinolone or a third-or-higher-generation cephalosporin must be combined with metronidazole; metronidazole alone (anaerobic cover only), or a cephalosporin or a quinolone alone, does not adequately treat infected necrosis. Perform cholecystectomy preferably before discharge for mild acute biliary pancreatitis, and after a second unexplained AP episode even without identified gallstones; reserve ERCP within 24h for AP complicated by cholangitis, with rectal indomethacin +/- pancreatic duct stent and periprocedural hydration to reduce post-ERCP pancreatitis risk. Check triglycerides when gallstones/alcohol are absent (>1000 mg/dL supports a hypertriglyceridemia etiology). For stable pancreatic necrosis, defer surgical, radiological, or endoscopic intervention 4-6 weeks to allow walling-off (step-up approach).

American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437 · reviewed 2026-07-20 ↗
Paik WH … Park DH · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
Endoscopy meta analysis · n=1,143 · Sep 1, 2026 · GIE · IF 8.0

Diagnostic Accuracy of the Endoscopic Grading of Gastric Intestinal Metaplasia for Detecting Extensive Disease: a Systematic Review and Meta-analysis.

New evidencesystematic reviewmeta-analysisbiomarkerendoscopy quality
Clinical takeawayConsider using EGGIM ≥5 during NBI/BLI endoscopy in adults undergoing upper gastrointestinal endoscopy to identify patients with extensive GIM (OLGIM III-IV) who may benefit from surveillance.
What it foundEGGIM cutoff ≥5 had 90% sensitivity and 92% specificity for detecting extensive GIM (OLGIM III-IV) compared to histological OLGIM staging, with a diagnostic odds ratio of 105.93 and AUC 0.96.
ContextConfirms EGGIM as a valid real-time endoscopic tool for risk stratification in gastric precancerous conditions, aligning with current interest in endoscopic staging over biopsy alone.
Reinforcessuggested applicable standard· European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34)

Decision at stakeusing the Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) score to risk-stratify patients

… Stage with validated endoscopic classifications of atrophy (e.g. Kimura-Takemoto) or intestinal metaplasia (e.g. EGGIM) to stratify gastric cancer risk (suggestion, weaker than the biopsy recommendation). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform individual gastric risk assessment and staging of precancerous conditions at first-time gastroscopy, irrespective of the patient's country of origin. Use high quality endoscopy with virtual chromoendoscopy (VCE), after proper training, for screening, diagnosis and staging of atrophy and intestinal metaplasia and after endoscopic therapy; VCE guides the biopsy site, with random biopsies taken only when there are no endoscopically suspected changes. Take biopsies from at least two topographic sites, 2 from the antrum/incisura and 2 from the corpus, VCE-guided, in two separate, clearly labeled vials; an additional incisura biopsy is optional, not required. Stage with validated endoscopic classifications of atrophy (e.g. Kimura-Takemoto) or intestinal metaplasia (e.g. EGGIM) to stratify gastric cancer risk (suggestion, weaker than the biopsy recommendation). Follow up patients with extensive endoscopic changes (Kimura C3+ or EGGIM 5+) OR an advanced histological stage that reaches OLGA/OLGIM III/IV, severe atrophy or intestinal metaplasia and/or significant changes in both antrum and corpus rising to stage III/IV, not any intestinal metaplasia or any antrum-plus-corpus involvement on its own, with high quality endoscopy every 3 years, irrespective of country of origin (strong recommendation, moderate quality). Propose NO surveillance for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history of gastric cancer, incomplete intestinal metaplasia, persistent H. pylori infection), the guideline states this group constitutes most individuals found in clinical practice. Eradicate H. pylori in all patients with precancerous conditions and after endoscopic or surgical therapy. Discontinue or do not start gastric cancer screening or surveillance in asymptomatic individuals over 80, and weigh comorbidities when planning treatment of superficial lesions. Advise smoking cessation; low-dose daily aspirin may be considered for gastric cancer prevention only in selected individuals already at high cardiovascular risk. For visible neoplasia, use ESD for differentiated lesions clinically staged as dysplastic (low or high grade) or intramucosal carcinoma (any size if not ulcerated, or ≤30 mm if ulcerated), with EMR an alternative for Paris 0-IIa lesions ≤10 mm with low likelihood of malignancy. At the population level, endoscopic screening is suggested every 2-3 years in high-risk regions (age-standardized rate >20 per 100,000 person-years), every 5 years in intermediate-risk regions (ASR 10-20) only if cost-effectiveness has been proven, and not at all in low-risk regions (ASR <10).

European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34) · reviewed 2026-07-23 ↗
Luu MN … Quach DT · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy retrospective · n=2,013 · Sep 1, 2026 · UEG Journal · IF 5.6

Dedicated Endoscopy for Barrett's Oesophagus With Higher Dysplasia Yield May Reduce Seattle Protocol Biopsies: Results From UK Multicentre Study.

New evidenceBarrett's esophagusendoscopy qualitysedation
Clinical takeawayConsider advocating for dedicated Barrett's surveillance services in your institution, as they demonstrated superior dysplasia detection (6.9% vs 2.8%) and lower complications compared to conventional services. Prioritize lesion recognition and targeted biopsies over strict Seattle protocol adherence when advanced imaging (NBI/AAC) identifies visible lesions.
What it foundDedicated Barrett's surveillance services (N=1037) detected dysplasia in 6.9% vs 2.8% in conventional services (N=976; p < 0.001), with higher use of NBI, AAC, and sedation, and significantly lower complication rates.
ContextMulticenter retrospective cohort (N=2013; mean age 64.4, mean BO length 4.1cm) challenges the necessity of rigid Seattle protocol adherence when advanced imaging is available in dedicated settings with higher lesion detection. Sedation use was high but complication rates were lower in the dedicated service.
Measured against the standard of care· AGA 2025 (surveillance) / ACG 2022 (diagnosis, endoscopic therapy, post-EET)

Decision at stakethe use of structured biopsy protocols like the Seattle protocol in Barrett's esophagus surveillance

… Implementation statements require a high-quality exam, a structured (Seattle-type) biopsy protocol, confirmation of any BE-related dysplasia by an expert GI pathologist, intervals tailored to segment length and dysplasia grade, and shared decision-making. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Surveillance practice is now defined by the AGA 2025 surveillance guideline (Wani et al., Gastroenterology 2025;169:1184-1231; endorsed by the Canadian Association of Gastroenterology). Its 8 GRADE recommendations are: (1) endoscopic surveillance for nondysplastic BE rather than none (conditional, low certainty); (2) NO endoscopic surveillance for columnar-lined esophagus <1 cm, even with intestinal metaplasia, when there is no neoplasia (conditional); (3) high-definition white-light endoscopy PLUS chromoendoscopy over white light alone (STRONG); (4) no recommendation for or against wide-area transepithelial sampling (WATS-3D) as an adjunct to structured biopsy; (5) no recommendation on p53 IHC and (6) no recommendation on TissueCypher as adjuncts to histopathology in NDBE, indefinite for dysplasia (IND), or LGD; (7) daily PPI over no PPI to prevent neoplastic progression (conditional); (8) PPI over antireflux surgery to prevent progression to HGD/EAC (conditional). Implementation statements require a high-quality exam, a structured (Seattle-type) biopsy protocol, confirmation of any BE-related dysplasia by an expert GI pathologist, intervals tailored to segment length and dysplasia grade, and shared decision-making. Surveillance should stop when a patient could not tolerate endoscopic therapy, surgery, or oncologic treatment for EAC, at any age. The AGA 2025 interval table could not be read directly (full text paywalled). Until it is, the intervals below are the ACG 2022 intervals, which remain consistent with AGA's segment-length framing: NDBE <3 cm every 5 years; NDBE >=3 cm every 3 years; IND, after a second-pathologist read, optimize to twice-daily PPI, repeat EGD within 6 months, then annually if IND persists; confirmed LGD on surveillance, EGD at 6 and 12 months, then annually. Diagnosis (IM plus >=1 cm columnar mucosa, no biopsy of a normal or <1 cm irregular Z line, >=8 biopsies), endoscopic eradication therapy (EET over esophagectomy for HGD/T1a (strong); EET suggested for confirmed LGD with surveillance an acceptable alternative; resect visible lesions before RFA; sm1 low-risk T1b may be considered for EET) and post-EET intervals (baseline LGD: 1 year, 3 years, then every 2 years; baseline HGD/T1a: 3, 6, 12 months, then annually) are still governed by ACG 2022. The AGA surveillance guideline does not address them, and AGA has said a separate screening guideline will follow in 2026.

AGA 2025 (surveillance) / ACG 2022 (diagnosis, endoscopic therapy, post-EET) · reviewed 2026-10-11 ↗
Gamakaranage C … DEBO group · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
Endoscopy retrospective · n=710 · Sep 1, 2026 · J Clin Gastro · IF 2.9

The Safety and Efficacy of Colorectal Endoscopic Submucosal Dissection in the Elderly: A Large Western Analysis of 710 Lesions.

New evidenceESDcolorectal cancerendoscopy quality
Clinical takeawayConsider colorectal ESD for Western elderly patients (≥75) with laterally spreading lesions, as it is safe and effective compared to younger cohorts despite higher comorbidities, antithrombotic use, and a slightly higher length of stay.
What it foundEn-bloc resection rates (87.4%, 80.9%, 80.2%) and R0 resection rates (69.6%, 68%, 61.5%) were comparable across age groups (<65, 65-75, ≥75), with no significant difference in adverse events (6.7%, 8.5%, 6.3%).
ContextConfirms safety and efficacy of ESD in Western elderly patients, extending prior Eastern data to a Western cohort with different patient and lesion characteristics.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

Decision at stakethe safety and efficacy of colorectal ESD in elderly patients

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Ayoub F … Othman M · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Endoscopy meta analysis · n=1,322 · Sep 1, 2026 · J Clin Gastro · IF 2.9

Performance, Efficacy, and Safety of Lubiprostone in Bowel Preparation Regimens: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

New evidencecolonoscopysystematic reviewmeta-analysis
Clinical takeawayConsider lubiprostone adjunct for patients undergoing colonoscopy, given its higher excellent prep rates without added risk, though it does not improve polyp detection.
What it foundLubiprostone adjunct bowel prep doubled excellent prep rates (OR 2.25, 95% CI 1.52-3.33) and reduced poor prep (P=0.009) compared to standard prep alone, with no difference in polyp detection, duration, or adverse events.
ContextConfirms lubiprostone's role in improving prep quality, a known challenge in colonoscopy, without altering detection or safety compared to standard prep.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Wu Y … Han A · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Endoscopy meta analysis · n=616 · Sep 1, 2026 · UEG Journal · IF 5.6

Immediate Versus On-Demand Direct Endoscopic Necrosectomy for Necrotizing Pancreatitis: A Systematic Review and Meta-Analysis.

New evidencemeta-analysisacute pancreatitisERCP
Clinical takeawayContinue current practice of on-demand DEN for necrotizing pancreatitis; no evidence supports switching to immediate DEN as a default strategy.
What it foundImmediate DEN did not significantly improve clinical success (OR 1.92, 95% CI 1.01-3.63) or other outcomes (technical success, need for drainage/surgery, adverse events, mortality) vs on-demand DEN in necrotizing pancreatitis.
ContextConfirms equipoise in DEN timing: prior evidence was mixed, but this meta-analysis (including 4 RCTs) finds no clear advantage to immediate intervention.
Reinforcessuggested applicable standard· American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437

Decision at stakethe timing of direct endoscopic necrosectomy for necrotizing pancreatitis

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnose acute pancreatitis (AP) by the Atlanta criteria (2 of 3: characteristic epigastric/LUQ pain, lipase or amylase >3x ULN [lipase preferred for specificity/duration], or characteristic imaging). ACG 2024 stratifies severity risk using SIRS on admission plus bedside risk factors, rising/elevated BUN, rising/elevated hematocrit (>44), obesity (BMI>30), extrapancreatic fluid collections/pleural effusion/infiltrates, altered mental status, and older age/comorbidities, rather than mandating a formal BISAP or APACHE II composite score. Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). Start oral low-fat solid food within 24-48h as tolerated in mild disease; if enteral feeding is needed for moderately severe/severe disease, prefer nasogastric over nasojejunal with small-peptide/medium-chain-triglyceride formula and continuous (not bolus/cyclic) feeding; avoid parenteral nutrition if possible. Do not give prophylactic antibiotics, even in severe disease or sterile necrosis; reserve antibiotics for suspected infected necrosis (typically arising 10-14 days in), and choose agents that penetrate pancreatic necrosis while together covering both gut-derived gram-negative enterics and anaerobes, a carbapenem supplies this as monotherapy, whereas a fluoroquinolone or a third-or-higher-generation cephalosporin must be combined with metronidazole; metronidazole alone (anaerobic cover only), or a cephalosporin or a quinolone alone, does not adequately treat infected necrosis. Perform cholecystectomy preferably before discharge for mild acute biliary pancreatitis, and after a second unexplained AP episode even without identified gallstones; reserve ERCP within 24h for AP complicated by cholangitis, with rectal indomethacin +/- pancreatic duct stent and periprocedural hydration to reduce post-ERCP pancreatitis risk. Check triglycerides when gallstones/alcohol are absent (>1000 mg/dL supports a hypertriglyceridemia etiology). For stable pancreatic necrosis, defer surgical, radiological, or endoscopic intervention 4-6 weeks to allow walling-off (step-up approach).

American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437 · reviewed 2026-07-20 ↗
Wang R … Li Z · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
Endoscopy guideline · Sep 1, 2026 · UEG Journal · IF 5.6

EUS-Guided Choledochoduodenostomy With Lumen-Apposing Metal Stents: A Recommendation From an Expert Delphi Consensus.

Guideline / reviewguidelinebiliary strictureEUS
Clinical takeawayConsider EUS-CDS-L as a preferred option for distal malignant biliary obstruction without gastric outlet obstruction, and as a therapeutic option for benign biliary obstruction. Adhere to expert-recommended procedural steps, including CBD diameter cutoff considerations (specific cutoff not stated in abstract), but note no evidence supports routine antibiotic prophylaxis.
What it foundExpert consensus (92.3% agreement, ≥80% agreement, median ≥4, IQR ≤1) recommends EUS-CDS-L for distal malignant biliary obstruction without gastric outlet obstruction, includes it as an option for benign obstruction, and supports use in patients scheduled for upfront surgery. Consensus also established a preferred common bile duct (CBD) diameter cutoff for safe EUS-CDS-L (specific cutoff not stated in abstract) and noted lack of evidence for routine antibiotic prophylaxis.
ContextRefines current practice by consolidating expert consensus on indications, procedural details, and safety considerations for EUS-CDS-L, an emerging but variably adopted technique.
Measured against the standard of care· ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis)

Decision at stakethe choice of biliary drainage method for distal malignant biliary obstruction without gastric outlet obstruction

… Malignant distal: drain before surgery only selectively (cholangitis, severe jaundice or pruritus, delayed surgery). … Endoscopic drainage is preferred over surgery or PTBD for inoperable obstruction. … Use plastic stents when the drainage strategy is undefined or the centre is not expert. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnosis is unchanged and still follows the separate ESGE diagnostic guideline (Endoscopy 2025;57:166-185). Start with MRI/MRCP plus laboratory tests, read CA19-9 only after decompression, and check IgG4 when IgG4-related sclerosing cholangitis is suspected. For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. For perihilar strictures, sample by ERCP first and move to cholangioscopy-guided biopsy if the result is indeterminate. Do not place an uncovered SEMS (USEMS) until malignancy is confirmed. Management now follows the 2026 ESGE biliary stricture management guideline, which replaces the 2018 stenting guideline and brings it into line with the 2022 therapeutic EUS guideline. Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. Anastomotic strictures after liver transplant get MPSs, or a temporary FCSEMS if more than 2 cm below the confluence. Nonanastomotic post-transplant strictures that can be treated endoscopically get MPSs plus balloon dilation if needed. Chronic pancreatitis strictures get a temporary 8-10 mm FCSEMS for 6-12 months. High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. Endotherapy is indicated for a benign stricture with liver tests raised for more than 1 month and/or cholangitis. Malignant distal: drain before surgery only selectively (cholangitis, severe jaundice or pruritus, delayed surgery). When drainage is needed before surgery or neoadjuvant therapy, or for palliation, place a 10-mm SEMS endoscopically. Endoscopic drainage is preferred over surgery or PTBD for inoperable obstruction. Malignant hilar: manage in high-volume centres with a hepatobiliary multidisciplinary team (MDT). ERCP is preferred over PTBD for preoperative drainage. Palliate Bismuth I-II with ERCP. For Bismuth III-IV, ERCP or ERCP combined with EUS-guided drainage (EUS-BD) is preferred over primary PTBD, with PTBD as a complement if needed. For proven Bismuth II-IV, aim to drain more than 50%, ideally 70% or more, of the viable nonatrophic liver volume using several routes as needed. Use plastic stents when the drainage strategy is undefined or the centre is not expert. USEMS are for expert centres when the diagnosis is proven, the tumour is unresectable, and complete drainage is predicted. After failed or unfeasible ERCP, EUS-BD is recommended over PTBD. Use hepaticogastrostomy (EUS-HGS) if there is a duodenal stricture, and EUS-HGS or choledochoduodenostomy (EUS-CDS) if there is not. PTBD is used if EUS-BD fails. In surgically altered anatomy, benign disease gets enteroscopy-assisted ERCP first; malignant disease gets enteroscopy-assisted ERCP or EUS-BD. Give antibiotics before ERCP in selected cases: predicted incomplete drainage, hilar strictures, immunocompromised patients, PSC, cholangioscopy. This follows the ESGE ERCP-adverse-events guideline. Etiology-specific care (Strasberg injuries, IgG4-SC, Mirizzi, choledochal cysts) is unchanged.

ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis) · reviewed 2026-10-11 ↗
Khoury T … Napoléon B · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
Endoscopy retrospective · n=496 · Sep 1, 2026 · UEG Journal · IF 5.6

EUS-Guided Gallbladder Drainage for Acute Cholecystitis in the Western World: Heterogeneity in Current Practice and the Relation With Patient Outcome.

New evidenceEUSERCPbiliary strictureendoscopy quality
Clinical takeawayFor EUS-GBD in AC patients unfit for surgery, prefer transduodenal access and LAMS >10mm when feasible; monitor for recurrent biliary disease (18.8% rate) and LAMS-related AEs (11.1%). Note 6.5% conversion to laparotomy risk if bridging to cholecystectomy.
What it foundTransduodenal EUS-GBD access had fewer LAMS-related AEs (SHR 0.42, 95% CI 0.23-0.76) and lower recurrent biliary disease vs transgastric access; LAMS >10mm reduced recurrent cholecystitis and mortality in patients unfit for surgery.
ContextRefines EUS-GBD technique: confirms transduodenal access safety from smaller studies and adds LAMS size data, though retrospective.
Refinessuggested applicable standard· American College of Gastroenterology, 'Diagnosis and Management of Choledocholithiasis', 2019

Decision at stakethe choice of gallbladder drainage method for acute cholecystitis in patients unfit for immediate surgery

… Obtain labs (CBC, CMP with LFTs, lipase, urinalysis, pregnancy test in reproductive-age women) and RUQ ultrasound as first imaging, then direct further workup by ultrasound findings, cholecystectomy for acute cholecystitis, MRCP for suspected choledocholithiasis based on risk stratification (e.g., high-risk criteria including CBD dilation >6 mm, bilirubin >4 mg/dL, or gallstone pancreatitis), CCK-HIDA/GBEF for acalculous functional gallbladder disorder, and cross-sectional imaging for liver masses or other pathology.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For right upper quadrant pain, characterize the pattern (acute vs chronic, post-meal vs unrelated, with vs without fever/jaundice) and triage acute red-flag presentations (Murphy sign, Charcot's triad, painless jaundice with weight loss, pregnancy with LFT/coagulation derangement) to the ED. Obtain labs (CBC, CMP with LFTs, lipase, urinalysis, pregnancy test in reproductive-age women) and RUQ ultrasound as first imaging, then direct further workup by ultrasound findings, cholecystectomy for acute cholecystitis, MRCP for suspected choledocholithiasis based on risk stratification (e.g., high-risk criteria including CBD dilation >6 mm, bilirubin >4 mg/dL, or gallstone pancreatitis), CCK-HIDA/GBEF for acalculous functional gallbladder disorder, and cross-sectional imaging for liver masses or other pathology.

American College of Gastroenterology, 'Diagnosis and Management of Choledocholithiasis', 2019 · reviewed 2026-07-21 ↗
De Wispelaere L … Hindryckx P · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
Endoscopy rct · n=110 · Sep 1, 2026 · Dig Endosc · IF 5.2

Submucosal Lidocaine Injection in Colonic Endoscopic Submucosal Dissection: A Single-Center, Double-Blind, Randomized Controlled Trial.

New evidenceESDcolorectal cancerendoscopy qualitysedation
Clinical takeawayConsider adding 1% lidocaine with 0.6% sodium alginate to submucosal injection fluid during colonic ESD to reduce spasms and antispasmodic use, particularly in cases with anticipated technical difficulty.
What it foundSubmucosal lidocaine injection (1% lidocaine with 0.6% sodium alginate) reduced severe spasms during colonic ESD compared to saline with 0.6% sodium alginate (34.6% vs 74.1%) and cut median antispasmodic doses from 2 to 1, without increasing adverse events.
ContextConfirms prior small studies suggesting lidocaine's antispasmodic effect in ESD, though without significant procedure time reduction in this adequately powered trial.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Ueda T … Seno H · Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society · IF 5.2 · PubMed ↗Permalink
Endoscopy prospective cohort · n=43 · Sep 4, 2026 · Dig Dis Sci · IF 2.5

Predictors of Progression to Villous Atrophy in Children with Type 1 Diabetes and Potential Celiac Disease.

New evidencepediatricbiomarkerbasic science
Clinical takeawayIn children with type 1 diabetes and positive celiac serology but a normal initial biopsy, reconsider initiating a gluten-free diet based solely on a TTG >10x ULN, as this study found only 26% of such patients progressed to villous atrophy at 1 year compared to watchful waiting with repeat serology and biopsy, which may be more appropriate. Monitor for potential risks of delayed diagnosis or progression.
What it foundIn children with type 1 diabetes and potential celiac disease, only 23% progressed to villous atrophy over a median of 12 months; a baseline γδ T cell/CD3 T cell ratio was the strongest predictor of progression (AUROC 0.918), while only 26% of those with TTG ≥10x ULN at baseline developed atrophy.
ContextChallenges the practice of initiating a gluten-free diet based on high TTG titers (>10x ULN) alone in children with type 1 diabetes and potential celiac disease, suggesting this threshold has low positive predictive value for villous atrophy in this specific population, where spontaneous seroreversion is common.
Refinessuggested applicable standard· American College of Gastroenterology (ACG), "American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease" (Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Greer KB, Limketkai BN, Lebwohl B), Am J Gastroenterol 2023;118(1):59-76, 2023

Decision at stakewhether to perform a biopsy in children with T1DM and potential celiac disease

… REFRACTORY CD (RCD) is a separate, rarer entity (<1% of patients outside referral centers): ongoing malabsorptive symptoms and signs with villous atrophy despite strict adherence to a GFD for MORE THAN 12 months and absence of other disorders including overt lymphoma; initial assessment centers on distinguishing RCD type 1 from type 2 by CD3/CD8 immunostains, T-cell receptor clonality by PCR, and/or flow cytometry of duodenal biopsies.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes VACCINATION.

Our full summary of this standard

DIAGNOSIS (patient must be on a gluten-containing diet). Serologic testing consists of TTG-IgA plus, if IgA deficiency has not previously been excluded, concurrent total IgA; if IgA deficiency is present, measure an IgG-based serology (DGP-IgG and/or TTG-IgG). This algorithm, previously restricted to those >=2 years, now applies to adults and children at ANY age. An elevated TTG-IgA should proceed to EGD with duodenal biopsy. A negative TTG-IgA in a non-IgA-deficient patient adequately rules out CD only when pretest probability is low or moderate; in symptomatic patients whose pretest suspicion is high (>5%), EGD with duodenal biopsy should be performed irrespective of serologic result. ACG recommends EGD with multiple duodenal biopsies to confirm the diagnosis in both children and adults with suspicion of CD (STRONG recommendation, moderate quality; 1 dissent); sampling should be 1 or 2 biopsies from the bulb (9-o'clock or 12-o'clock position) and at least 4 from the distal duodenum. Lymphocytic duodenosis (>=25 IELs/100 epithelial cells) without villous atrophy is NOT specific for CD. NONBIOPSY PATHWAY (CONDITIONAL recommendation, moderate quality): a combination of high-level TTG-IgA (>10x ULN) with a positive EMA in a SECOND blood sample is suggested as reliable for diagnosis in CHILDREN, and only if the family agrees with the no-biopsy strategy; in SYMPTOMATIC ADULTS unwilling or unable to undergo upper GI endoscopy the same criteria may be considered AFTER THE FACT, as a diagnosis of 'likely CD', ACG does not endorse a prospective no-biopsy pathway in adults, noting a >=10-fold TTG-IgA elevation carries a PPV of only ~95% in adults, which may be unacceptably low given lifelong treatment implications. HLA-DQ2/DQ8 is not required for diagnosis but is useful for serology-histology discrepancy or in patients already on a GFD; if negative, CD is ruled out. TREATMENT AND MONITORING. Strict lifelong GFD. A visit with a dietitian after diagnosis is MANDATORY, with subsequent visits as needed to reinforce education and adherence encouraged; interview with a dietitian experienced in the GFD is the standard of care for assessing adherence. ACG RECOMMENDS consumption of gluten-free oats (STRONG recommendation, moderate quality), with the qualifier that gluten contamination of oats, variable toxicity across oat varieties, and a small risk of immune reaction to avenin require monitoring for oat tolerance (monitoring intervals are not known). ACG suggests AGAINST routine use of gluten detection devices in food or biospecimens (conditional, low quality; 1 dissent), and finds INSUFFICIENT EVIDENCE to recommend for or against probiotics (evidence gap). ACG suggests setting a goal of intestinal healing as an end point of GFD therapy, advocating individualized discussion of goals beyond clinical and serological remission (CONDITIONAL recommendation, low quality). Follow-up may require multiple visits in the first year (e.g. 3, 6, and 12 months) and regular visits (e.g. twice a year or yearly) thereafter, tracking symptoms and TTG or DGP serology; other tests may include CBC, ALT, AST, vitamins A/D/E/B12, copper, zinc, folic acid, ferritin, and iron, with follow-up bloodwork individualized to verify correction of values abnormal at baseline. Preventive care includes vaccines and DXA. Symptoms improve within days of strict adherence (diarrhea improved in 80% within 60 days), but mucosal healing lags: median time from GFD onset to mucosal healing in adults is 3 years, so it is reasonable to consider a follow-up biopsy in adults after 2 years of starting a GFD, in the ABSENCE of symptoms, after shared decision-making; children heal faster (95% within 2 years), altering the risk-benefit calculus. Repeat biopsy is the only reliable method to document mucosal healing, seroconversion correlates poorly. Upper endoscopy with biopsies is also indicated for lack of clinical response or relapse of symptoms despite a GFD. VACCINATION: ACG suggests vaccination to prevent pneumococcal disease in patients with CD (CONDITIONAL recommendation, low quality), because increased pneumococcal risk is attributed to hyposplenism (frequently subclinical) present in roughly one-third of patients. The regimen follows CDC recommendations by age, immunization record, and comorbidity: for an adult with CD and functional asplenia not previously vaccinated or with unknown history, 1 dose of PCV15 (followed by PPSV23 at least 1 year later) or 1 dose of PCV20 (no PPSV23 indicated); for an adult with CD and no other condition carrying a specific CDC recommendation, ACG suggests 1 dose of PCV20 alone, or 1 dose of PCV15 first and then consider PPSV23 at least 1 year later. NONRESPONSIVE CD (NRCD): defined as persistent symptoms, signs, or laboratory abnormalities typical of CD despite 6-12 MONTHS of dietary gluten avoidance. Evaluation should review and confirm the initial diagnosis of CD, assess for inadvertent gluten exposure (via expert dietitian assessment and serology, positive serologies despite 12 months of GFD suggest ongoing gluten ingestion), assess for a coexisting functional disorder, and selectively test based on clinical suspicion for food intolerances (e.g. lactose, fructose), pancreatic insufficiency, microscopic colitis, and small intestinal bacterial overgrowth, among others. REFRACTORY CD (RCD) is a separate, rarer entity (<1% of patients outside referral centers): ongoing malabsorptive symptoms and signs with villous atrophy despite strict adherence to a GFD for MORE THAN 12 months and absence of other disorders including overt lymphoma; initial assessment centers on distinguishing RCD type 1 from type 2 by CD3/CD8 immunostains, T-cell receptor clonality by PCR, and/or flow cytometry of duodenal biopsies.

American College of Gastroenterology (ACG), "American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease" (Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Greer KB, Limketkai BN, Lebwohl B), Am J Gastroenterol 2023;118(1):59-76, 2023 · reviewed 2026-07-19 ↗
Neelamegam M … Thunga C · Digestive Diseases and Sciences · IF 2.5 · PubMed ↗Permalink
Endoscopy meta analysis · n=3,197 · Sep 1, 2026 · J Clin Gastro · IF 2.9

Proficiency in Esophageal Peroral Endoscopic Myotomy: A Meta-Analysis of Learning Curves.

New evidencemeta-analysisendoscopy qualitycomputer-aided detection
Clinical takeawayTraining programs can use these metrics to set benchmarks for POEM proficiency, aiming for procedure times around 80 minutes and myotomy speeds of approximately 7.71 minutes per cm after 33 procedures.
What it foundPOEM learners achieved proficiency in procedure speed after 33 procedures, with plateau procedure time at 80.25 minutes and myotomy speed at 7.71 minutes per cm, compared to earlier phases of learning (0-20 procedures).
ContextThis meta-analysis confirms prior evidence on POEM learning curves, providing precise metrics for proficiency and plateau performance in gastroenterologists undergoing POEM training.
Refinessuggested applicable standard· American College of Gastroenterology (ACG), Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. "ACG Clinical Guidelines: Diagnosis and Management of Achalasia." Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi:10.14309/ajg.0000000000000731

Decision at stakethe choice of POEM as a treatment option for achalasia

… SURVEILLANCE: ACG recommends AGAINST routine endoscopic surveillance for esophageal carcinoma in patients with achalasia (strong, low), although risk is elevated (~1 cancer per 300 patient-years), absolute numbers are low, an estimated >400 endoscopies would be needed to detect one cancer, and surveillance has not demonstrated improved survival.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes TREATMENT, FOLLOW-UP, RETREATMENT.

Our full summary of this standard

Evaluate for achalasia any patient with dysphagia to solids and liquids, regurgitation, or chest pain, and specifically consider it in patients presumed to have GERD who do not respond to acid suppression (strong recommendation, very low quality). Diagnose with high-resolution manometry using esophageal pressure topography rather than conventional line tracings (strong, high). Subtype by Chicago Classification (I, II, III), this is a conditional recommendation (low quality): subtyping may inform prognosis and treatment choice, with type II having the most favorable outcomes and type III requiring a longer/tailored myotomy; ACG does not make subtyping mandatory for diagnosis. Always perform upper endoscopy in suspected achalasia to exclude pseudoachalasia from an obstructing mass; use cross-sectional imaging and/or endoscopic ultrasound in difficult cases (ACG states this as narrative guidance, not a numbered recommendation, and specifies no biopsy protocol). FLIP is described as complementary, useful in patients who cannot tolerate manometry and as an arbiter in difficult cases where manometry fails to diagnose achalasia despite high clinical suspicion, not as a required confirmatory test. TREATMENT: pneumatic dilation is superior to medical therapy for symptom relief and esophageal emptying (strong, very low). PD and laparoscopic Heller myotomy are both effective and equivalent short- and long-term for patients who are candidates for definitive therapy (strong, high). POEM and LHM give comparable symptomatic improvement (strong, moderate). POEM and PD give comparable symptomatic improvement in type I or II (conditional, low). For type III, tailored POEM or LHM is recommended as a more efficacious disruptive LES therapy than PD (strong, moderate), ACG does NOT single out POEM over LHM for type III. When surgical myotomy is performed, add fundoplication: myotomy with fundoplication is superior to myotomy alone for controlling distal esophageal acid exposure (strong, moderate), using either Dor or Toupet (conditional, moderate). Botulinum toxin injection is first-line therapy for patients unfit for definitive therapy (strong, moderate), and prior botulinum toxin does not significantly compromise subsequent myotomy performance or outcomes (strong, low). POEM carries a higher incidence of GERD than LHM with fundoplication or PD (strong, moderate). Do not place stents for long-term dysphagia (strong, low). Reserve esophagectomy for surgically fit patients with megaesophagus who have failed other interventions (strong, low), and consider Heller myotomy before esophagectomy in patients who failed PD and POEM when the anatomy is conducive and there is evidence of incomplete myotomy (strong, very low). FOLLOW-UP: use timed barium esophagram as the first-line test to evaluate continued or recurrent symptoms after definitive therapy (strong, very low); the Eckardt score alone or HRM alone should not be used to define treatment failure. Do not obtain routine gastrografin esophagram after dilation, reserve it for clinical suspicion of perforation (strong, low). RETREATMENT: PD is appropriate and safe after failed surgical myotomy or POEM (strong, moderate), and POEM is safe in patients who previously underwent PD or LHM (strong, low). SURVEILLANCE: ACG recommends AGAINST routine endoscopic surveillance for esophageal carcinoma in patients with achalasia (strong, low), although risk is elevated (~1 cancer per 300 patient-years), absolute numbers are low, an estimated >400 endoscopies would be needed to detect one cancer, and surveillance has not demonstrated improved survival.

American College of Gastroenterology (ACG), Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. "ACG Clinical Guidelines: Diagnosis and Management of Achalasia." Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi:10.14309/ajg.0000000000000731 · reviewed 2026-07-19 ↗
Wu Y … Ramai D · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Endoscopy retrospective · n=145 · Sep 5, 2026 · Dig Dis Sci · IF 2.5

Association Between Arterial Calcification and Small Bowel Vascular Lesions: A Comparative Study of Angioectasia and Dieulafoy's Lesions.

New evidencecapsule endoscopyhemostasis
Clinical takeawayConsider assessing arterial calcification (e.g., via CT-based Agatston score) in patients with Type 1 small-bowel vascular lesions to identify those at higher rebleeding risk, though further evidence is needed to guide clinical action based on these findings.
What it foundType 1 small-bowel vascular lesions had higher superior mesenteric artery calcification (61% vs. 33%, P=0.033) and median modified Agatston scores (8154 vs. 377, P=0.039), with scores ≥7502 associated with increased rebleeding risk (P=0.028).
ContextThis study refines understanding of small-bowel vascular lesions in 145 patients diagnosed via double-balloon enteroscopy, linking Type 1 lesions to systemic arteriosclerosis and rebleeding risk, contrasting with Type 2 lesions' association with acute bleeding.
Refinessuggested applicable standard· European Society of Gastrointestinal Endoscopy (ESGE), "Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, Update 2022", Endoscopy 2023;55(1):58-95, 2022/2023

Decision at stakethe management of small bowel vascular lesions identified during device assisted enteroscopy

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Suspected small-bowel bleeding (SSBB), bleeding between the ampulla of Vater and the ileocecal valve, suspected when GI bleeding persists after negative upper and lower endoscopy. Small-bowel capsule endoscopy (SBCE) is recommended as the FIRST-LINE examination, before other endoscopic and radiological tests (strong, moderate). ESGE does NOT recommend routine second-look endoscopy prior to SBCE in suspected small-bowel bleeding or iron-deficiency anemia (strong, low). In OVERT suspected small-bowel bleeding, perform SBCE as soon as possible after the bleeding episode, ideally within 48 hours, to maximize diagnostic and therapeutic yield (strong, high). Device-assisted enteroscopy (DAE) is recommended to confirm and possibly treat lesions identified by SBCE (strong, high); in overt suspected small-bowel bleeding, DAE should optimally be performed within 48-72 hours of the bleeding episode (strong, high). Where SBCE is unavailable or contraindicated, DAE and/or dedicated small-bowel cross-sectional imaging may be considered first, depending on availability, expertise and clinical suspicion (weak, low). After a HIGH-QUALITY NEGATIVE SBCE, ESGE recommends conservative management (strong, moderate), the 2015 wording qualified this as patients without ongoing bleeding evidenced by overt bleeding or continued transfusion requirement, and the 2022 update carries this qualifier as a separate companion recommendation: for patients with a high-quality negative SBCE who have ONGOING overt bleeding or a continued need for blood transfusions, ESGE recommends further investigation using repeat SBCE, DAE, or dedicated small-bowel cross-sectional imaging (strong, moderate). SBCE is also recommended first-line in iron-deficiency anemia when small-bowel evaluation is indicated (strong, high), and after unremarkable or nondiagnostic dedicated small-bowel cross-sectional imaging if likely to influence management (strong, low). CROHN'S DISEASE: in SUSPECTED Crohn's with negative ileocolonoscopy, SBCE is the initial small-bowel modality ONLY in the absence of obstructive symptoms or known bowel stenosis (strong, high); in that group ESGE explicitly does NOT recommend routine cross-sectional imaging or a patency capsule before SBCE (strong, HIGH quality). With obstructive symptoms or known stenosis, dedicated cross-sectional imaging (MRE/MR-enteroclysis or CTE/CT-enteroclysis) is used FIRST (strong, moderate), and a patency capsule is recommended before SBCE in suspected Crohn's with obstructive symptoms (strong, low), even when cross-sectional imaging is negative. In ESTABLISHED Crohn's, a patency capsule before SBCE is recommended to decrease the retention rate (strong, moderate). SMALL-BOWEL TUMORS: SBCE is recommended where there is increased risk of a small-bowel tumor (strong, moderate); ESGE does NOT recommend specific investigations before SBCE in suspected small-bowel tumor UNLESS the patient is considered at risk of capsule retention (strong, low). If imaging has ALREADY demonstrated a suspected small-bowel tumor, DAE is preferred over SBCE (strong, low). Cross-sectional imaging is recommended for staging and operability when SBCE shows a tumor with high diagnostic certainty (strong, low); where the capsule diagnosis is uncertain, biopsy sampling AND tattooing of the location by DAE is recommended (strong, low); for a subepithelial mass, confirm by DAE and/or cross-sectional imaging per local availability/expertise (strong, low). SBCE is NOT recommended for follow-up of treated small-bowel tumors, for lack of data (strong, low). PATENCY/RETENTION generally: GI obstruction is an absolute contraindication to SBCE. If the patency capsule is egested intact, retention of a real capsule is unlikely; if not egested within 30 hours, cross-sectional imaging (not plain abdominal radiography) is favored to localize it. In Peutz-Jeghers syndrome, routine patency capsule use is NOT recommended and should be considered case-by-case.

European Society of Gastrointestinal Endoscopy (ESGE), "Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, Update 2022", Endoscopy 2023;55(1):58-95, 2022/2023 · reviewed 2026-07-23 ↗
Shigenobu S … Oka S · Digestive Diseases and Sciences · IF 2.5 · PubMed ↗Permalink
Endoscopy rct · n=40 · Sep 1, 2026 · Pancreas · IF 1.9

Endoscopic Ultrasound-Guided Transluminal Drainage of Walled-Off Necrosis Using Naso-Cystic Drain With Metal Stent Versus Metal Stent Alone: A Randomized Controlled Pilot Study.

New evidenceEUSendoscopy quality
Clinical takeawayDo not routinely add nasocystic drainage to EUS-guided LAMS for WON; LAMS alone is non-inferior and may shorten hospitalization. However, these findings are exploratory and require confirmation in larger trials.
What it foundAdding nasocystic drainage (NCD) to EUS-guided LAMS for walled-off necrosis (WON) did not improve clinical success compared to LAMS alone (55% vs 45% at day 3, P=0.527) and prolonged median hospital stay (specific duration not provided, P=0.038).
ContextChallenges the uncertain role of NCD as an adjunct to LAMS, suggesting it adds no benefit in WON drainage. Findings are exploratory due to small sample size and baseline imbalance.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Kar N … Gautam V · Pancreas · IF 1.9 · PubMed ↗Permalink
Endoscopy retrospective · n=3,298 · Sep 1, 2026 · UEG Journal · IF 5.6

Evolution of Endoscopic and Histologic Assessment of Eosinophilic Esophagitis in Europe and Evolution of the Diagnostic Delay: Data From the EUREOS EoE CONNECT Registry.

New evidenceeosinophilic esophagitisendoscopy qualityepidemiologybiomarker
Clinical takeawayObtain biopsies from at least two esophageal segments (distal and middle) when evaluating for EoE to maximize diagnostic sensitivity, as recommended by current guidelines.
What it foundDistal esophageal biopsies had the highest diagnostic sensitivity for EoE, and sampling that included the distal segment achieved sensitivity above 97%, particularly when combined with middle esophageal biopsies, compared to single-segment sampling.
ContextConfirms and refines current guideline recommendations for multi-segment biopsy sampling in EoE, showing improved diagnostic yield and reduced diagnostic delay with adherence in a European multicenter cohort.
Measured against the standard of care· ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417)

Decision at stakeobtaining at least 6 esophageal biopsies from at least 2 esophageal levels for EoE diagnosis

… DIAGNOSIS: symptoms of esophageal dysfunction plus ≥15 eos/hpf after excluding other causes of esophageal eosinophilia. A PPI trial is not a diagnostic criterion (PPI-REE abandoned). Do the initial diagnostic EGD off PPI, topical steroid and dietary therapy (ACG key concept; ASGE consensus, which gives no washout duration). Initial assessment is a standard EGD, not a less-invasive modality, so that full biopsies and dilation are possible (ASGE). Take ≥6 esophageal biopsies from ≥2 levels in anyone with symptoms or endoscopic findings consistent with EoE, targeting visible lesions. In CHILDREN with suspected EoE, also biopsy the stomach and duodenum (ASGE). Use EREFS at every endoscopy and report a quantified peak eosinophil count (ACG strong/low; ASGE). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes TREATMENT (ACG), DILATION, MAINTENANCE and 2 more.

Our full summary of this standard

ACG 2025 (GRADE) is still the governing guideline. The ASGE 2026 consensus Part 2 (modified Delphi, 28 statements at ≥80% agreement; not GRADE) adds endoscopic and pediatric detail without contradicting it. DIAGNOSIS: symptoms of esophageal dysfunction plus ≥15 eos/hpf after excluding other causes of esophageal eosinophilia. A PPI trial is not a diagnostic criterion (PPI-REE abandoned). Do the initial diagnostic EGD off PPI, topical steroid and dietary therapy (ACG key concept; ASGE consensus, which gives no washout duration). Initial assessment is a standard EGD, not a less-invasive modality, so that full biopsies and dilation are possible (ASGE). Take ≥6 esophageal biopsies from ≥2 levels in anyone with symptoms or endoscopic findings consistent with EoE, targeting visible lesions. In CHILDREN with suspected EoE, also biopsy the stomach and duodenum (ASGE). Use EREFS at every endoscopy and report a quantified peak eosinophil count (ACG strong/low; ASGE). TREATMENT (ACG): swallowed topical steroids STRONG/moderate; high-dose PPI CONDITIONAL/low; empiric elimination diet CONDITIONAL/low. Choose a single initial therapy by shared decision-making. Fluticasone or budesonide are both reasonable. Adult doses: PPI double the reflux dose (e.g., omeprazole 20 mg BID or 40 mg daily); budesonide 2-4 mg/day (BOS 2 mg BID); fluticasone 1,760 mcg/day divided. Pediatric doses: PPI 2 mg/kg/day; budesonide 1-2 mg/day; fluticasone 110-880 mcg/day. Allergy testing is not used to direct diets. A 1FED/2FED step-up diet with a dietitian is acceptable, with endoscopic and biopsy confirmation after each reintroduced food. Dupilumab is CONDITIONAL for PPI-nonresponsive patients aged ≥12 (moderate) and for ages 1-11 at ≥15 kg (low). Weight-band dosing: 15-<30 kg 200 mg q2w; 30-<40 kg 300 mg q2w; ≥40 kg 300 mg weekly. Recommendations AGAINST: omalizumab, cromolyn, montelukast. No recommendation for cendakimab, benralizumab, lirentelimab, mepolizumab or reslizumab. DILATION: an adjunct to anti-inflammatory therapy for strictures causing dysphagia (ACG conditional/low). Start low and go slow; target ≥16 mm in adults and adolescents over ≥1 session. In children, ASGE supports dilation of symptomatic strictures or a narrow-caliber esophagus regardless of disease activity, using the same start-low/go-slow approach. MAINTENANCE: continue effective therapy (ACG STRONG despite low evidence) at the lowest effective dose. MONITORING: judge response on symptoms, endoscopy and histology together, never symptoms alone. Assess response endoscopically at 8-12 weeks after starting a PPI or topical steroid. For diet, ACG says 8-12 weeks and ASGE says 6-8 weeks. For dupilumab or biologics, assess at 12-24 weeks (ASGE: up to 24 weeks). Allow appropriate washout or timing after any treatment change before the follow-up EGD (ASGE). Take monitoring biopsies from the most severe-appearing lesions (rings, furrows, exudates) (ASGE). Monitoring biopsies may be limited to the esophagus when prior gastric and duodenal biopsies were normal and nothing new suggests other pathology (ASGE). The histologic response threshold of <15 eos/hpf is a 'may consider' target, read alongside endoscopic and symptom findings. Shorten follow-up after complications. Care gaps of ≥2 years are associated with fibrostenosis. PEDIATRIC (ACG): esophagram for children with dysphagia to assess fibrostenotic disease; feeding therapy and dietitian for feeding dysfunction; growth, development and nutrition are treatment goals.

ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417) · reviewed 2026-10-11 ↗
Grueso-Navarro E … Lucendo AJ · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
← Back to issue №10 Every section of this issue is one click away, at the top of this page. Follow Endoscopy by RSS